Introduction
I come to you this morning not as an intellectual property lawyer but as a former general counsel of biotechnology and pharmaceutical related companies, as an attorney with significant exposure to intellectual property issues and as one who has seen first-hand the importance of intellectual property in shaping commercial strategies in biotechnology. With that as a backdrop, I would like to thank you for allowing me the opportunity to share with you today thoughts that I have regarding patents and the impact of patent reform on biotechnology. It has been said that the best way to predict the future is to invent it. However, I believe that the best way to control the future is to patent it.
The existence of patents and patent law policy is, on one level, to protect patent holders and their discoveries while, on another level, it exists to foster innovation while facilitating and promoting the inventive process and commercialization. 1 In addition, patents and patent law reform policy assist firms, small and large, in attracting venture capital by signaling that a firm possesses valuable knowledge capital. While patents and the associated policies and reforms have impacted the direction of many technology driven industries, there is no one area greater than biotechnology where its influence is felt. Although a relatively young and emerging sector of the global economy, 4 biotechnology, along with its innovation and investment, depends on a reliable and strong intellectual property system generally and a robust global patent system specifically. Patents enable biotechnology firms to increase their expected profits from investments in research and development while fostering innovation that would not occur but for the existence of the patent. 5 Patents, moreover, promote the dissemination of scientific and technical information that would otherwise be unavailable but for the prospect of the patent. 6 In short, as indicated by World Intellectual Property Organization, patents are a mechanism that encourages creative activity, industrialization, investment, and honest trade thereby, contributing more to our global safety and comfort, less poverty and more beauty in our lives. The strength of a robust patent system and the protections accorded by such a system is rationalized by several goals. They include, 1) incentivizing creativity; 2) rewarding creativity; 3) providing rights to patent owners for the fruit of their creative labor; 4) satisfying principles of moral and natural rights; 5) promoting public disclosure of new information; 6) facilitating transfer of innovation; All of these policy and reform activities have, as a result, added a level of uncertainty to patent procurement, enforcement and business decision making. Clearly, the biotechnology industry, in its relative infancy, is confronted with challenges as it navigates through the myriad of patent related reforms and, in some cases, general public and political opposition to biotechnology patents. To understand these challenges, it is important to understand the development of patent law and patent policy in addition to the global demand for biotechnology and the impact of changes on biotechnology investment and innovation.
As we turn our attention to patent Law and Policy Development, we understand that the global demand for biotechnology and its resultant products is significant. This demand is driven by the needs of a growing and aging world population and by the innovation that emerges from patent laws and policies. 7 To fully appreciate patent laws and policies, it is important to understand the historical context from which they have evolved. reform that took place between the 1600s and 1800s there was a fundamental shift in British patent policy -a reform that went from viewing patents as a contract between the crown and the patentee to viewing patents as a social contract between the patentee and society. In short, the British patents evolved from being a royal prerogative to a system based on and adjudicated by common law courts to a system that is rooted in statute representing a legal right obtained by an inventor for the exclusive control over his invention.
18
Unlike the British system of patent law which had its beginnings in royal prerogatives, the American patent law and policy is rooted in legislation and administrative procedure. 19 ability of any person to 1) petition certain governmental officials to obtain a patent for an invention or discovery; 2) deliver to governmental officials a specification in writing "containing a description" of the invention to be patented; 3) petition for a patent for a term not exceeding a specified number of years; 4) petition for a patent on an invention that is sufficiently useful and important; 5) be accorded an evidentiary presumption favoring the patentee; and 6) be charged a fixed fee for filing a patent application. The TRIPS Agreement introduced intellectual property law into the international trading system for the first time, and remains the most comprehensive international agreement on intellectual property to date.
TRIPS requires member countries to grant patents in all fields of technology, subject to the normal test of novelty, inventiveness and industrial applicability and without regard to the place of the invention. 25 TRIPS also allows member countries to, among other things, enforce intellectual property rights through trade sanctions. 26 The TRIPS Agreement specifies the subject matter to be protected, the minimum duration of protection as being twenty years, the rights to be conferred and permissible exceptions. as visualized from a three dimensional perspective and as depicted in Figure   5 . In this regard, consideration of patents is given in terms of 1) legal scope -considering the scope of exclusive rights in the covered subject matter;
2) geographical range -considering validity of rights in various countries; and 3) duration -considering the length or duration of the rights derived from the patent. Notwithstanding the growth rate in total patent filings, the gap in the global distribution of biotechnology patents and innovation between the United States and the rest of the world has remained relatively constant. 47 To close this gap, it requires a greater diffusion of ideas which leads to newer ideas through the expansion of public domain knowledge on which others can build. It is a cycle, as depicted in Figure 6 that results in the creation of new works from existing knowledge with sharing and establishing a new threshold for innovation. 47 Id.
Key Patent Activities Affecting Biotechnology
As we turn to key patent activities affecting biotechnology, it is important to note that U.S. leadership in biotechnology has benefited historically from a strong intellectual property environment. Policies 
First-to-File
With respect to a first-to-file system of patents, many hurdles and problems encountered by inventors in general could be minimized or eliminated. The United States is currently the only country in the world that gives priority to the application that claims the earliest invention date i.e. 48 Hermans et al., supra note 39, at 266.
"first person to invent," regardless of which application arrives first. A firstto-file system as opposed to "first person to invent" system would provide certainty in the patent application process by a clear metric of a filing date.
First-to-file would eliminate costly interference proceedings used to determine priority of invention dates, and it would harmonize US patent practice with the rest of the world, especially with the European Patent
Office and the Japan Patent Office.
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However, a first-to-file patent system may not be the best for biotechnology or small inventors. Because of their complexity, biotechnology inventions may take a long time to develop, and a race to the patent office under a first-to-file system would likely lead to patent applications that do not satisfy the requirements for enablement and written description. Moreover, small inventors may lack the resources for expedited research and patent filings which would be necessary for success under a first-to-file system.
Continuation Applications
In the case of Continuation Applications, it is a well-settled practice in practice. 52 Preserving the practice of filing unlimited continuation applications will allow biotechnology and other science-based firms to develop and implement the best patent procurement strategies.
Injunctive Relief
Turning to injunctive relief, the issuance of permanent injunctions by trial courts in the U.S. has been a practice which is consistent with the fundamental right to exclude others from making, using, offering for sale or selling a patented invention. 
Issues to Watch -Final Thoughts
As I bring this discussion to a conclusion, I would like to share with you some final thoughts regarding issues to watch. As we discussed, at the broadest level biotechnology is an industry that includes innovation and commercialization that are supported by patents. This act permits compulsory patent licensing when a recipient of federal grants and contracts has not taken, or is not expected to take within a reasonable time, effective steps to achieve practical applications of the subject invention. Attempts have also been made to carve out a compulsory licensing remedy judicially such as in the eBay case where the courts have utilized a public interest test in determining whether injunctive relief should be granted -the effect of which is compulsory licensing. In the European Union, the issue of compulsory licensing is murky, notwithstanding the existence of the Doha Declaration which allows for compulsory licensing in developed countries for the manufacture of patented drugs. 65 Lastly, proposed legislation for bio-generics or bio-similars 66 should be carefully followed by the biotechnology industry. There is no current regulatory pathway for bio-generic products in the United States, although the European Union has enacted some regulations. Bio-generic and bio-similar regulations over the coming years will have a huge impact on the competitive landscape for biotechnology products.
Conclusion
In conclusion, the global intellectual property system, since the days of the Venetians, has evolved from a system of sectarian interest and parochial politics to one which is open to ensuring innovation throughout the world. More specifically, the international patent system "has entered a brave new scientific epoch" 67 in which scientists, inventors, researchers, jurists and business persons are beginning to understand how best to treat the daunting array of discoveries emerging from biotechnology. 68 With the U.S.
patent system as the standard bearer and TRIPS as the global enforcer, innovation and the commercialization of biotechnology will not only be ensured, but it will also be guaranteed that life-saving medicines and other related products, which are a result of patented discoveries, will reach those in world who are most in need. The global patent system as we know it is not a perfect system but it is one that holds promise for success and one that 67 Reichman and Dreyfuss, supra note 3, at 129. 68 Id.
will allow us, as a world community, to heal, fuel and feed this planet we all share.
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Thank you for this opportunity to speak. I am happy to respond to any questions that you may have at this time.
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